Case selection for statins was similar in two Canadian provinces: BC and Ontario

Journal of Clinical Epidemiology

Volumn 60, Issue 1, 2007, Pages 73-78

  Paterson, J Michael ^a   Carney, Greg ^a   Anderson, Geoffrey M ^a   Bassett, Ken ^a   Naglie, Gary ^a   Laupacis, Andreas ^a  

^a NONE

Author keywords

Geographic variation; Health policy; Pharmacoepidemiology; Population health; Prevention; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CANADA; CORONARY RISK; DATA BASE; DIABETES MELLITUS; DRUG COST; DRUG WITHDRAWAL; HEALTH CARE POLICY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL PRACTICE; OUTPATIENT; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; TIME SERIES ANALYSIS;

AGED; BRITISH COLUMBIA; CORONARY DISEASE; DRUG UTILIZATION; EPIDEMIOLOGIC METHODS; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; ONTARIO; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG;

EID: 33845246363     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2006.04.007     Document Type: Article

References (47)

1. Chassin M.R., Brook R.H., Park R.E., Keesey J., Fink A., Kosecoff J., et al. Variations in the use of medical and surgical services by the Medicare population. N Engl J Med 314 (1986) 285-290
2. In: Naylor C.D., Anderson G.M., and Goel V. (Eds). Patterns of health care in Ontario. 1st edition (1994), Canadian Medical Association, Ottawa 69-136
3. Roos N.P., Roos Jr. L.L., and Henteleff P.D. Elective surgical rates-do high rates mean lower standards? Tonsillectomy and adenoidectomy in Manitoba. N Engl J Med 297 (1977) 360-365
4. Chassin M.R., Kosecoff J., Park R.E., Winslow C.M., Kahn K.L., Merrick N.J., et al. Does inappropriate use explain geographic variations in the use of health care services? A study of three procedures. JAMA 258 (1987) 2533-2537
5. Leape L.L., Park R.E., Solomon D.H., Chassin M.R., Kosecoff J., and Brook R.H. Does inappropriate use explain small-area variations in the use of health care services?. JAMA 263 (1990) 669-672
6. van Walraven C.V., Paterson J.M., Kapral M., Chan B., Bell M., Hawker G., et al. Appropriateness of primary total hip and knee replacements in regions of Ontario with high and low utilization rates. CMAJ 155 (1996) 697-706
7. Hawker G.A., Wright J.G., Coyte P.C., Williams J.I., Harvey B., Glazier R., et al. Determining the need for hip and knee arthroplasty: the role of clinical severity and patients' preferences. Med Care 39 (2001) 206-216
8. Restuccia J.D., Shwartz M., Kreger B.E., Payne S.M., Ash A.S., Iezzoni L.I., et al. Does more "appropriateness" explain higher rates of cardiac procedures among patients hospitalized with coronary heart disease?. Med Care 40 (2002) 500-509
9. Kennedy J., Quan H., Ghali W.A., and Feasby T.E. Variations in rates of appropriate and inappropriate carotid endarterectomy for stroke prevention in 4 Canadian provinces. CMAJ 171 (2004) 455-459
10. Marciniak T.A., Ellerbeck E.F., Radford M.J., Kresowik T.F., Gold J.A., Krumholz H.M., et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 279 (1998) 1351-1357
11. Tu J.V., Austin P., Rochon P., and Zhang H. Secondary prevention after acute myocardial infarction, congestive heart failure, and coronary artery bypass graft surgery in Ontario. In: Naylor C.D., and Slaughter P.M. (Eds). Cardiovascular health and services in Ontario: an ICES Atlas (1999), Institute for Clinical Evaluative Sciences, Toronto 199-238
12. Morgan S. Sources of variation in provincial drug spending. CMAJ 170 (2004) 329-330
13. Jackevicius C.A., Tu K., Filate W.A., Brien S.E., and Tu J.V. Canadian Cardiovascular Outcomes Research Team. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Cardiol 19 (2003) 1359-1366
14. Pilote L., Beck C.A., Karp I., Alter D., Austin P., Cox J., et al. Canadian Cardiovascular Outcomes Research Team. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000. Can J Cardiol 20 (2004) 61-67
15. Fischer M.A., Schneeweiss S., Avorn J., and Solomon D.H. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 351 (2004) 2187-2194
16. Majeed A., Moser K., and Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 22 (2000) 275-279
17. Baxter C., Jones R., and Corr L. Time trend analysis and variations in prescribing lipid-lowering drugs in general practice. BMJ 317 (1998) 1134-1135
18. Anderson G.M., Bassett K., and the BC-Ontario Pharmacosurveillance for Decision-making Collaborative. Incorporating pharmacosurveillance in provincial drug formulary decision making: investigative report, June 2005. Accessed March 29, 2006. Available at:. http://www.ices.on.ca/webpage.cfm?site_id=1&org_id=68
19. Walley T., Folino-Gallo P., Schwabe U., van Ganse E., and EuroMedStat group. Variations and increase in use of statins across Europe: data from administrative databases. BMJ 328 (2004) 385-386
20. Therapeutics Initiative. Do statins have a role in primary prevention?. Ther Lett 48 (2003). http://www.ti.ubc.ca Accessed November 22, 2004. Available at:
21. Therapeutics Initiative. Statin's benefit for secondary prevention confirmed. What is the optimal dosing strategy?. Ther Lett 49 (2003). http://www.ti.ubc.ca Accessed November 22, 2004. Available at:
22. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
23. IMS Health. IMS Health Reports 11.5 percent dollar growth in 2003 prescription sales. Accessed November 22, 2004. Available at:. http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_3665_4477 1558,00.html
24. Simons L.A., Levis G., and Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 164 (1996) 208-211
25. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462-467
26. Canadian Institute for Health Information. Drug expenditure in Canada, 1985 to 2003 (2004), Canadian Institute for Health Information, Ottawa
27. Laupacis A., Paterson J.M., Mamdani M., Rostom A., and Anderson G.M. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach. CMAJ 169 (2003) 1167-1170
28. Levy A.R., O'Brien B.J., Sellors C., Grootendorst P., and Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10 (2003) 67-71
29. Tamblyn R., Lavoie G., Petrella L., and Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48 (1995) 999-1009
30. McCormack J.P., and Rangno R.E. An evaluation and critique of the use of lipid-lowering drugs in a population base of 400,000 patients over the age of 65. Can J Clin Pharmacol 1 (1994) 27-32
31. Savoie I., and Kazanjian A. Utilization of lipid-lowering drugs in men and women. A reflection of the research evidence?. J Clin Epidemiol 55 (2002) 95-101
32. Levy A.R., O'Brien B.J., McMullen E., May F.W., Demers C., Marshall D., et al. Rapid increase in statins newly dispensed to Ontario seniors between 1994 and 2000. Can J Cardiol 19 (2003) 665-669
33. Grootendorst P. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: History and assessment. Can J Clin Pharmacol 9 (2002) 79-99
34. Levy A.R., Tamblyn R.M., Fitchett D., McLeod P.J., and Hanley J.A. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol 15 (1999) 1277-1282
35. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
36. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al., CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
37. National Diabetes Surveillance System (NDSS) [on-line]. Ottawa: Public Health Agency of Canada; 2004. Accessed November 25, 2005. Available at: http://www.ndss.ca.
38. Hux J.E., Ivis F., Flintoff V., and Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25 (2002) 512-516
39. Statistics Canada. Estimates of population, by age group and sex, Canada, provinces and territories. Accessed November 25, 2004. Available at: http://www.statcan.ca.
40. Reid F.D., Cook D.G., and Whincup P.H. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?. Heart 88 (2002) 15-19
41. Cardiovascular disease mortality/hospital separations, Cardiovascular Disease Surveillance On-Line. Ottawa: Public Health Agency of Canada. Accessed October 20, 2005. Available at: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/cvd/index_e.html.
42. Health Canada. Canadians and heart health (1995), Minister of Supply and Services Canada, Ottawa, ON. http://www.med.mun.ca/chhdbc/public.htm Accessed October 20, 2005. Available at:
43. Tanuseputro P., Manuel D.G., Leung M., Nguyen K., and Johansen H. Canadian Cardiovascular Outcomes Research Team. Risk factors for cardiovascular disease in Canada. Can J Cardiol 19 (2003) 1249-1259
44. Canadian health measures survey. Ottawa, ON: Statistics Canada. Accessed October 20, 2005. Available at: http://www.statcan.ca/english/concepts/hs/measures.htm.
45. Tamblyn R., Laprise R., Hanley J.A., Abrahamowicz M., Scott S., Mayo N., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285 (2001) 421-429
46. Pilote L., Beck C., Richard H., and Eisenberg M.J. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. CMAJ 167 (2002) 246-252
47. Productivity Commission 2005. Impacts of advances in medical technology in Australia. Melbourne: Commonwealth of Australia. Accessed October 20, 2005. Available at: http://www.pc.gov.au/study/medicaltechnology/finalreport.